President and Chief Executive Officer
John J. Sperzel joined Chembio Diagnostic Systems, Inc. in March 2014, and serves as President and Chief Executive Officer (CEO) and as a member of the Board of Directors. Prior to joining the company, Mr. Sperzel served as President and CEO at ITC, a Point of Care Diagnostics company owned by Warburg Pincus. He previously held executive leadership positions at Axis-Shield, Bayer Diagnostics, Instrumentation Laboratory and Boehringer Mannheim. Mr. Sperzel received a B.S. in Business Administration/Management from Plymouth State College and serves as an advisor to the Board of the Diagnostic Marketing Association.
Richard J. Larkin
Chief Financial Officer
Richard J. Larkin joined Chembio Diagnostic Systems, Inc. in September 2003, and serves as Chief Financial Officer (CFO). Prior to joining the company, Mr. Larkin served as CFO at Visual Technology Group. He previously served as CFO at Protex International Corporation. Mr. Larkin received a BBA in Accounting from Dowling College and is a member of the American Institute of Certified Public Accountants.
President, Americas Region
Sharon Klugewicz joined Chembio Diagnostic Systems, Inc. in September 2012, and serves as President, Americas Region, following her promotion from Chief Operating Officer, where she is responsible for regional sales, marketing, and customer support, as well as global clinical and regulatory affairs, and global quality systems. Prior to joining the company, Ms. Klugewicz served as Sr. Vice President, Scientific & Laboratory Services at Pall Corporation. She previously held executive leadership positions in the Pall Life Sciences Division, including Global Quality Operations, Field Technical Services, Marketing, and Product Management. Ms. Klugewicz received a B.S. in Neurobiology from Stony Brook University and a M.S. in Biochemistry from Adelphi University.
Robert Passas Ph.D.
President, EMEA and APAC Regions
Bob Passas joined Chembio Diagnostic Systems, Inc. in October 2016, and serves as President, EMEA and APAC Regions, where he is responsible for regional sales, marketing, and customer support. Prior to joining the company, Dr. Passas served as Vice President, Worldwide Marketing and International Sales at Trinity Biotech. He previously held executive leadership positions Abbott, Quidel, and The Binding Site. Dr. Passas received a B.S. in Medical Biochemistry and a Ph.D. in Analytical Chemistry from the University of Surrey, UK.
Chief Science and Technology Officer
Javan Esfandiari joined Chembio Diagnostic Systems, Inc. in February 2000, and serves as Chief Science and Technology Officer. Prior to joining the company, Mr. Esfandiari co-founded Sinovus Biotech AB, a Swedish biotech company where he served as Director of R&D until Chembio acquired Sinovus. He previously served as Director of R&D for On-Site Biotech. Mr. Esfandiari is the inventor of Chembio’s patented Dual Path Platform (DPP®) technology and developed more than 30 rapid point-of-care diagnostic products in the human and veterinary fields. Mr. Esfandiari received a B.S. in Clinical Chemistry and studied to M. Sc. Level in Molecular Biology from Lund University, Sweden.
VP, Regulatory Affairs
Tom Ippolito joined Chembio Diagnostic Systems, Inc. in June 2005, and serves as Vice President, Regulatory Affairs. Prior to joining the company, Mr. Ippolito served as Vice President, Regulatory and Quality at Biospecifics Technologies. He previously held a number of positions with United Biomedical, Biospecifics, Merck, Rhone Merieux, Organon Teknika, Analytab Products Inc., and Olympus. Mr. Ippolito holds the position of Course Director of the Fundamentals of Bioscience Program at the State University of Stony Brook and is the instructor for clinical development and regulatory affairs.
VP, Product Development
Paul Lambotte joined Chembio Diagnostic Systems, Inc. in December 2014, and serves as Vice President of Product Development. Prior to joining the company, Mr. Lambotte was President of PLC Inc., a POC product development consulting company. He previously served as Chief Science Officer at Axxin Pty Ltd, held positions of VP of R&D and Business Development at Quidel Corporation, and held a number of positions at Beckman Coulter and Hybritech Inc. Mr. Lambotte is the inventor of several patents in the field of rapid, point-of-care diagnostic products. He received a Master in Biochemistry and a PhD in Protein Biochemistry from the University of Mons, Belgium, and did post-doctoral work at the Ludwig Institute for Cancer research in Brussels, Belgium.